Iluvien fluocinolone acetonide intravitreal implant: Completed Phase III enrollment

pSivida completed enrollment of 120 patients in a double-blind, sham-controlled, international Phase III trial evaluating 0.18 mg intravitreal Iluvien. The trial

Read the full 212 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE